Complete Genomics Demonstrates Its Technology’s Potential by Sequencing 14 Human Genomes for Customers
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Complete Genomics Inc. has announced that it has sequenced, analyzed and delivered 14 human genomes to customers since March 2009. Considering that fewer than 20 genomes have been sequenced and published in the world to date, this is a significant advance both for Complete Genomics and medical research.
Complete Genomics currently has more than a dozen customers using its high-quality, low-cost human genome sequencing technology to conduct small pilot projects, each comprised of five to 10 genomes. These customers represent a mix of academic research institutions and biopharmaceutical companies and include Pfizer, the Flanders Institute for Biotechnology (VIB), Duke University, Brigham & Women’s Hospital, the HudsonAlpha Institute for Biotechnology, and the Ontario Institute for Cancer Research in addition to the previously announced Institute for Systems Biology and Broad Institute of MIT and Harvard.
These customers have embraced Complete Genomics’ business model which allows them simply to send DNA samples to the company and receive their requested genome data. Because customers do not need to purchase instruments or reagents, it can reduce cost and complexity of sequencing complete human genomes.
Complete Genomics’ customers are using the pilot projects to evaluate the company’s technology and also to conduct small-scale disease studies to investigate conditions as diverse as cancer, HIV and schizophrenia.
In the cancer studies, researchers are comparing patients’ tumor genome with their non-cancerous genome to identify variations that may provide insights into the cause or spread of their disease. The goal is to use this previously unavailable whole genome data to characterize the tumor and identify its vulnerabilities. These data can then be used to design more effective therapies for patients.
Scaling Up
Complete Genomics is conducting its customer pilot projects using its existing R&D sequencing instruments. However, the company is also in the process of scaling up its genome center and transitioning to a commercial operation. After its commercial launch in January 2010, Complete Genomics will conduct much larger sequencing projects and employ new commercial-scale instruments that will be able to read well over one terabase (1012 bases) per run.
Complete Genomics will achieve this goal by increasing the efficiency of its technology on multiple levels. The company is building higher-density DNA nanoarrays (DNBs) that will contain 2.85 billion spots of DNA arranged in a grid with 70 bases per spot, allowing it to sequence an entire human genome on a single array. It is also developing new sequencing instruments that will be able to read the sequences from multiple DNA nanoarrays concurrently, thereby sequencing well over one terabase in a single run.
The company’s high-volume genomic sequencing will naturally generate massive amounts of data, which will be managed and analyzed in its data center using its proprietary software on a high-performance computing cluster.
The key to Complete Genomics’ success is its sharp focus on providing only complete human genome sequencing in a massively parallel process. By optimizing all of its systems for this one task, the company is strongly positioned to become the dominant supplier of large-scale human genomic data.
Complete Genomics currently has more than a dozen customers using its high-quality, low-cost human genome sequencing technology to conduct small pilot projects, each comprised of five to 10 genomes. These customers represent a mix of academic research institutions and biopharmaceutical companies and include Pfizer, the Flanders Institute for Biotechnology (VIB), Duke University, Brigham & Women’s Hospital, the HudsonAlpha Institute for Biotechnology, and the Ontario Institute for Cancer Research in addition to the previously announced Institute for Systems Biology and Broad Institute of MIT and Harvard.
These customers have embraced Complete Genomics’ business model which allows them simply to send DNA samples to the company and receive their requested genome data. Because customers do not need to purchase instruments or reagents, it can reduce cost and complexity of sequencing complete human genomes.
Complete Genomics’ customers are using the pilot projects to evaluate the company’s technology and also to conduct small-scale disease studies to investigate conditions as diverse as cancer, HIV and schizophrenia.
In the cancer studies, researchers are comparing patients’ tumor genome with their non-cancerous genome to identify variations that may provide insights into the cause or spread of their disease. The goal is to use this previously unavailable whole genome data to characterize the tumor and identify its vulnerabilities. These data can then be used to design more effective therapies for patients.
Scaling Up
Complete Genomics is conducting its customer pilot projects using its existing R&D sequencing instruments. However, the company is also in the process of scaling up its genome center and transitioning to a commercial operation. After its commercial launch in January 2010, Complete Genomics will conduct much larger sequencing projects and employ new commercial-scale instruments that will be able to read well over one terabase (1012 bases) per run.
Complete Genomics will achieve this goal by increasing the efficiency of its technology on multiple levels. The company is building higher-density DNA nanoarrays (DNBs) that will contain 2.85 billion spots of DNA arranged in a grid with 70 bases per spot, allowing it to sequence an entire human genome on a single array. It is also developing new sequencing instruments that will be able to read the sequences from multiple DNA nanoarrays concurrently, thereby sequencing well over one terabase in a single run.
The company’s high-volume genomic sequencing will naturally generate massive amounts of data, which will be managed and analyzed in its data center using its proprietary software on a high-performance computing cluster.
The key to Complete Genomics’ success is its sharp focus on providing only complete human genome sequencing in a massively parallel process. By optimizing all of its systems for this one task, the company is strongly positioned to become the dominant supplier of large-scale human genomic data.
